METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS
Aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents. More particularly, aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents using tapioca starch or related compounds. Lipophilic active agents include cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins.
1 - 21 . (canceled)
22 . A lipophilic active agent infused food product comprising:
(a) a therapeutically effective amount of a lipophilic active agent, wherein the lipophilic active agent is selected from the group consisting of a cannabinoid, nicotine, a non-steroidal anti-inflammatory drug (NSAID), and a vitamin;
(b) an edible oil or fat;
(c) a starch, wherein the starch is selected from the group consisting of tapioca starch, corn starch, potato starch, oxidized starch, starch ester, starch ether, crosslinked starch, alpha starch, octenylsuccinate ester, and processed starch obtained by treating a starch by an acid, heat, or enzyme; and
(d) a food product, wherein the food product is selected from the group consisting of tea leaves, coffee beans, cocoa powder, meats, fish, fruits, vegetables, dairy products, legumes, pastas, breads, grains, seeds, nuts, spices, and herbs.
23 . The lipophilic active agent infused food product of claim 1 obtainable by the steps of:
(i) contacting the food product with an edible oil comprising the lipophilic active agent; and
(ii) dehydrating the food product, wherein dehydrating comprises contacting the food product with the starch;
thereby producing the lipophilic active agent infused food product.
24 . The lipophilic active agent infused food product of claim 2 , wherein step (i) comprises saturating the food product in the edible oil comprising the lipophilic active agent.
25 . The lipophilic active agent infused food product of claim 3 , further comprising a bioavailability enhancing agent, wherein the bioavailability enhancing agent enhances the bioavailability of the lipophilic active agent.
26 . The lipophilic active agent infused food product of claim 4 , wherein step (i) comprises saturating the food product in an edible oil comprising the lipophilic active agent and the bioavailability enhancing agent.
27 . The lipophilic active agent infused food product of claim 1 , wherein the lipophilic active agent is a nonpsychoactive cannabinoid.
28 . The lipophilic active agent infused food product of claim 1 , wherein the lipophilic active agent is an NSAID selected from the group consisting of acetylsalicylic acid, ibuprophen, diclofenac, indomethacin, and piroxicam.
29 . The lipophilic active agent infused food product of claim 1 , wherein the lipophilic active agent is vitamin E.
30 . A lipophilic active agent infused beverage product obtainable by the steps of:
(i) providing lipophilic active agent infused tea leaves, coffee beans, or cocoa powder according to claim 1 ; and
(ii) steeping the lipophilic active agent infused tea leaves, coffee beans, or cocoa powder in a liquid;
thereby producing the lipophilic active agent infused beverage product.
31 . A process for making a lipophilic active agent infused food product comprising the steps of:
(i) contacting a food product with an oil comprising a lipophilic active agent; and
(ii) dehydrating the food product, wherein dehydrating comprises contacting the food product with a starch selected from the group consisting of tapioca starch, corn starch, potato starch, oxidized starch, starch ester, starch ether, crosslinked starch, alpha starch, octenylsuccinate ester, and processed starch obtained by treating a starch by an acid, heat, or enzyme;
thereby producing the lipophilic active agent infused food product; wherein the lipophilic active agent infused food product comprises a therapeutically effective amount of the lipophilic active agent, and further wherein:
(a) the lipophilic active agent is selected from the group consisting of a cannabinoid, nicotine, a non-steroidal anti-inflammatory drug (NSAID), and a vitamin; and
(b) the food product is selected from the group consisting of tea leaves, coffee beans, cocoa powder, meats, fish, fruits, vegetables, dairy products, legumes, pastas, breads, grains, seeds, nuts, spices, and herbs.
32 . The process of claim 31 , wherein step (i) further comprises contacting the food product with a bioavailability enhancing agent, wherein the bioavailability enhancing agent enhances the bioavailability of the lipophilic active agent.
33 . A process for making a lipophilic active agent infused beverage product comprising:
(i) providing lipophilic active agent infused tea leaves, coffee beans, or cocoa powder according to claim 1 ; and
(ii) steeping the lipophilic active agent infused tea leaves, coffee beans, or cocoa powder in a liquid;
thereby producing the lipophilic active agent infused beverage product.
34 . A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a lipophilic active agent, wherein the lipophilic active agent is selected from the group consisting of a cannabinoid, nicotine, a non-steroidal anti-inflammatory drug (NSAID), and a vitamin;
(b) an edible oil or fat; and
(c) a starch, wherein the starch is selected from the group consisting of tapioca starch, corn starch, potato starch, oxidized starch, starch ester, starch ether, crosslinked starch, alpha starch, octenylsuccinate ester, and processed starch obtained by treating a starch by an acid, heat, or enzyme.
35 . The pharmaceutical composition of claim 34 , further comprising a bioavailability enhancing agent, wherein the bioavailability enhancing agent enhances the bioavailability of the lipophilic active agent.
36 . The pharmaceutical composition of claim 34 , wherein the lipophilic active agent is a nonpsychoactive cannabinoid.
37 . The pharmaceutical composition of claim 34 , wherein the lipophilic active agent is an NSAID selected from the group consisting of acetylsalicylic acid, ibuprophen, diclofenac, indomethacin, and piroxicam.
38 . The pharmaceutical composition of claim 34 , wherein the lipophilic active agent is vitamin E.
39 . The pharmaceutical composition of claim 34 , wherein the pharmaceutical composition is formulated for oral administration.
40 . The pharmaceutical composition of claim 39 , wherein the pharmaceutical composition is formulated as a tablet, pill, capsule, liquid, gel, syrup, or slurry.
41 . A method of treating a condition comprising administering the lipophilic active agent infused food product, lipophilic active agent infused beverage product, or pharmaceutical composition of claim 1 to a subject in need thereof, wherein the lipophilic active agent is a cannabinoid, and wherein the condition is selected from the group consisting of cardiac diseases such as heart disease, ischemic infarcts, and cardiometabolic disorders; neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, and Human Immunodeficiency Virus (HIV) dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer chemotherapy; benign prostatic hypertrophy; irritable bowel syndrome; biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine, or cocaine addiction.
42 . A method of enhancing the bioavailability of a lipophilic active agent, comprising heating the lipophilic active agent infused food product, lipophilic active agent infused beverage product, or pharmaceutical composition of claim 1 to a temperature that is greater than or equal to human body temperature, wherein the method comprises oral administration of the lipophilic active agent infused food product to a human subject.